HCTC
MCID: THY096
MIFTS: 27

Thyroid Carcinoma, Hurthle Cell (HCTC)

Categories: Cancer diseases, Endocrine diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Thyroid Carcinoma, Hurthle Cell

MalaCards integrated aliases for Thyroid Carcinoma, Hurthle Cell:

Name: Thyroid Carcinoma, Hurthle Cell 58 54 13 56
Hurthle Cell Carcinoma of Thyroid 30 6 41
Thyroid Hurthle Cell Carcinoma 12 15 74
Hurthle Cell Thyroid Neoplasia 58 76
Thyroid Cancer, Hurthle Cell 54 45
Thyroid Cancer, Follicular, Hurthle Cell Type 54
Follicular Thyroid Cancer, Hurthle Cell Type 54
Hurthle Cell Carcinoma of the Thyroid 54
Oncocytic Carcinoma of the Thyroid 12
Hurthle Cell Thyroid Carcinoma 76
Hurthle Cell Thyroid Cancer 54
Adenocarcinoma, Oxyphilic 74
Hurthle Cell Carcinoma 76
Hctc 76

Classifications:



External Ids:

Disease Ontology 12 DOID:8161
OMIM 58 607464
NCIt 51 C4946
MedGen 43 C0749424

Summaries for Thyroid Carcinoma, Hurthle Cell

OMIM : 58 Hurthle cell carcinoma of the thyroid accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms (Sanders and Silverman, 1998). Hurthle cell tumors, also known as oxyphil cell tumors, are composed of cells with increased numbers of mitochondria, which corresponds morphologically to their voluminous, granular, eosinophilic cytoplasm (Maximo et al., 2005). (607464)

MalaCards based summary : Thyroid Carcinoma, Hurthle Cell, also known as hurthle cell carcinoma of thyroid, is related to thyroid cancer and liposarcoma. An important gene associated with Thyroid Carcinoma, Hurthle Cell is NDUFA13 (NADH:Ubiquinone Oxidoreductase Subunit A13). The drugs Iodine and Trace Elements have been mentioned in the context of this disorder. Affiliated tissues include thyroid.

UniProtKB/Swiss-Prot : 76 Hurthle cell thyroid carcinoma: A rare type of thyroid cancer accounting for only about 3-10% of all differentiated thyroid cancers. These neoplasms are considered a variant of follicular carcinoma of the thyroid and are referred to as follicular carcinoma, oxyphilic type.

Related Diseases for Thyroid Carcinoma, Hurthle Cell

Diseases related to Thyroid Carcinoma, Hurthle Cell via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 thyroid cancer 10.3
2 liposarcoma 10.1
3 hemangiopericytoma, malignant 10.1
4 goiter 10.0
5 patulous eustachian tube 10.0
6 mononeuritis multiplex 10.0
7 papillary carcinoma 10.0
8 differentiated thyroid carcinoma 9.5 NDUFA13 TG

Graphical network of the top 20 diseases related to Thyroid Carcinoma, Hurthle Cell:



Diseases related to Thyroid Carcinoma, Hurthle Cell

Symptoms & Phenotypes for Thyroid Carcinoma, Hurthle Cell

Clinical features from OMIM:

607464

Drugs & Therapeutics for Thyroid Carcinoma, Hurthle Cell

Drugs for Thyroid Carcinoma, Hurthle Cell (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 2, Phase 3 7553-56-2 807
2 Trace Elements Phase 2, Phase 3
3 Micronutrients Phase 2, Phase 3
4 Anti-Infective Agents Phase 2, Phase 3
5 cadexomer iodine Phase 2, Phase 3
6 Anti-Infective Agents, Local Phase 2, Phase 3
7 Nutrients Phase 2, Phase 3
8
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
9
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
10
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
11
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
12
Lenvatinib Approved, Investigational Phase 2 417716-92-8
13
Pembrolizumab Approved Phase 2 1374853-91-4
14
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
15 Protein Kinase Inhibitors Phase 2
16 Antifungal Agents Phase 2
17 Antibiotics, Antitubercular Phase 2
18 Immunologic Factors Phase 2
19 Anti-Bacterial Agents Phase 2
20 Immunosuppressive Agents Phase 2
21 Antineoplastic Agents, Immunological Phase 2
22 Angiogenesis Inhibitors Phase 2
23 Angiogenesis Modulating Agents Phase 2
24
Imetelstat Phase 2
25
Motesanib diphosphate Phase 2 850649-62-6 11450633
26
Rosiglitazone Approved, Investigational Phase 1 122320-73-4 77999
27 Hypoglycemic Agents Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists
29 Hormones
30 Hormone Antagonists

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients Recruiting NCT01398085 Phase 2, Phase 3
2 Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer Recruiting NCT02143726 Phase 2 sorafenib;everolimus
3 Lenvatinib and Pembrolizumab in DTC Recruiting NCT02973997 Phase 2 Lenvatinib
4 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer Completed NCT01811212 Phase 2 Cabozantinib S-malate
5 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery Active, not recruiting NCT00381641 Phase 2 Sunitinib Malate
6 A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer Completed NCT00121628 Phase 2 AMG 706
7 A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors Completed NCT01100619 Phase 1 rosiglitazone;XL184
8 Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment Completed NCT01441154
9 Studies on Tumors of the Thyroid Recruiting NCT00001160

Search NIH Clinical Center for Thyroid Carcinoma, Hurthle Cell

Cochrane evidence based reviews: thyroid cancer, hurthle cell

Genetic Tests for Thyroid Carcinoma, Hurthle Cell

Genetic tests related to Thyroid Carcinoma, Hurthle Cell:

# Genetic test Affiliating Genes
1 Hurthle Cell Carcinoma of Thyroid 30 NDUFA13

Anatomical Context for Thyroid Carcinoma, Hurthle Cell

MalaCards organs/tissues related to Thyroid Carcinoma, Hurthle Cell:

42
Thyroid

Publications for Thyroid Carcinoma, Hurthle Cell

Articles related to Thyroid Carcinoma, Hurthle Cell:

# Title Authors Year
1
Diffuse toxic goiter and coexisting hurthle cell carcinoma of thyroid presenting as lower limb weakness from mononeuritis multiplex. ( 27728172 )
2016

Variations for Thyroid Carcinoma, Hurthle Cell

ClinVar genetic disease variations for Thyroid Carcinoma, Hurthle Cell:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 NDUFA13 NM_015965.6(NDUFA13): c.15G> C (p.Lys5Asn) single nucleotide variant Pathogenic rs137852869 GRCh37 Chromosome 19, 19627062: 19627062
2 NDUFA13 NM_015965.6(NDUFA13): c.15G> C (p.Lys5Asn) single nucleotide variant Pathogenic rs137852869 GRCh38 Chromosome 19, 19516253: 19516253

Cosmic variations for Thyroid Carcinoma, Hurthle Cell:

9 (show top 50) (show all 278)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM34008 VHL thyroid,NS,carcinoma,follicular carcinoma c.232A>T p.N78Y 3:10142079-10142079 0
2 COSM7340067 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1859C>A p.T620N 14:81143917-81143917 0
3 COSM26419 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1897G>T p.D633Y 14:81143955-81143955 0
4 COSM26449 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1358T>C p.M453T 14:81143416-81143416 0
5 COSM26455 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1891T>A p.F631I 14:81143949-81143949 0
6 COSM26485 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1894A>G p.T632A 14:81143952-81143952 0
7 COSM26418 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1895C>T p.T632I 14:81143953-81143953 0
8 COSM26450 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1456A>T p.I486F 14:81143514-81143514 0
9 COSM26416 TSHR thyroid,NS,carcinoma,follicular carcinoma c.1867G>T p.A623S 14:81143925-81143925 0
10 COSM26489 TSHR thyroid,NS,carcinoma,Hurthle cell carcinoma c.2029C>G p.L677V 14:81144087-81144087 0
11 COSM6955563 TSC1 thyroid,NS,carcinoma,follicular carcinoma c.257G>T p.R86L 9:132925693-132925693 0
12 COSM20429 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9809G>A p.R3270H 7:98993628-98993628 0
13 COSM7340048 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.10688C>A p.S3563Y 7:99008440-99008440 0
14 COSM7339368 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.9227T>C p.I3076T 7:98984957-98984957 0
15 COSM7340052 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.776C>G p.A259G 7:98899743-98899743 0
16 COSM6472133 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.8662C>T p.R2888C 7:98981871-98981871 0
17 COSM7340050 TRRAP thyroid,NS,carcinoma,follicular carcinoma c.4520C>T p.P1507L 7:98948267-98948267 0
18 COSM7339759 TP53BP1 thyroid,NS,carcinoma,follicular carcinoma c.3739C>A p.R1247S 15:43428090-43428090 0
19 COSM10648 TP53 thyroid,NS,carcinoma,follicular carcinoma c.524G>A p.R175H 17:7675088-7675088 0
20 COSM10646 TP53 thyroid,NS,carcinoma,follicular carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
21 COSM11183 TP53 thyroid,NS,carcinoma,follicular carcinoma c.799C>T p.R267W 17:7673821-7673821 0
22 COSM10742 TP53 thyroid,NS,carcinoma,follicular carcinoma c.578A>G p.H193R 17:7674953-7674953 0
23 COSM10656 TP53 thyroid,NS,carcinoma,follicular carcinoma c.742C>T p.R248W 17:7674221-7674221 0
24 COSM10704 TP53 thyroid,NS,carcinoma,follicular carcinoma c.844C>T p.R282W 17:7673776-7673776 0
25 COSM11071 TP53 thyroid,NS,carcinoma,follicular carcinoma c.1009C>T p.R337C 17:7670700-7670700 0
26 COSM43624 TP53 thyroid,NS,carcinoma,follicular carcinoma c.875A>G p.K292R 17:7673745-7673745 0
27 COSM466080 TNKS2 thyroid,NS,carcinoma,follicular carcinoma c.3037A>G p.R1013G 10:91857473-91857473 0
28 COSM7339896 TNKS thyroid,NS,carcinoma,follicular carcinoma c.1969G>C p.A657P 8:9726688-9726688 0
29 COSM7340383 TAF1 thyroid,NS,carcinoma,follicular carcinoma c.587A>T p.E196V 23:71377067-71377067 0
30 COSM377895 STK11 thyroid,NS,carcinoma,follicular carcinoma c.662C>T p.P221L 19:1220645-1220645 0
31 COSM6943090 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.1100T>G p.F367C 23:124051203-124051203 0
32 COSM7340010 STAG2 thyroid,NS,carcinoma,follicular carcinoma c.456C>G p.F152L 23:124042639-124042639 0
33 COSM7339957 SPTA1 thyroid,NS,carcinoma,follicular carcinoma c.2944G>T p.V982F 1:158654703-158654703 0
34 COSM1639597 SPEN thyroid,NS,carcinoma,follicular carcinoma c.3793C>T p.R1265* 1:15930033-15930033 0
35 COSM7340270 SPEN thyroid,NS,carcinoma,follicular carcinoma c.971C>G p.S324* 1:15909410-15909410 0
36 COSM7340015 SNCAIP thyroid,NS,carcinoma,follicular carcinoma c.460C>A p.L154M 5:122423197-122423197 0
37 COSM5880107 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.1060G>C p.V354L 18:51065527-51065527 0
38 COSM14191 SMAD4 thyroid,NS,carcinoma,Hurthle cell carcinoma c.1016T>C p.F339S 18:51065483-51065483 0
39 COSM14190 SMAD4 thyroid,NS,carcinoma,Hurthle cell carcinoma c.992T>C p.M331T 18:51065459-51065459 0
40 COSM5546625 SMAD4 thyroid,NS,carcinoma,follicular carcinoma c.767A>T p.Q256L 18:51058224-51058224 0
41 COSM7339583 SH2B3 thyroid,NS,carcinoma,follicular carcinoma c.640G>A p.G214R 12:111418785-111418785 0
42 COSM7339476 SF3B1 thyroid,NS,carcinoma,follicular carcinoma c.635C>T p.P212L 2:197416772-197416772 0
43 COSM7340173 SETD2 thyroid,NS,carcinoma,follicular carcinoma c.3559G>A p.G1187R 3:47098029-47098029 0
44 COSM7340349 ROS1 thyroid,NS,carcinoma,follicular carcinoma c.578T>C p.V193A 6:117397116-117397116 0
45 COSM7339687 RNF43 thyroid,NS,carcinoma,follicular carcinoma c.1082C>T p.P361L 17:58358694-58358694 0
46 COSM1570338 RET thyroid,NS,carcinoma,follicular carcinoma c.2651A>T p.E884V 10:43120124-43120124 0
47 COSM5500823 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2269C>T p.Q757* 23:47185544-47185544 0
48 COSM4965696 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.1693+1G>A p.? 23:47181867-47181867 0
49 COSM7339411 RBM10 thyroid,NS,carcinoma,follicular carcinoma c.2266T>G p.W756G 23:47185541-47185541 0
50 COSM5546623 RB1 thyroid,NS,carcinoma,follicular carcinoma c.2039T>C p.I680T 13:48459766-48459766 0

Expression for Thyroid Carcinoma, Hurthle Cell

Search GEO for disease gene expression data for Thyroid Carcinoma, Hurthle Cell.

Pathways for Thyroid Carcinoma, Hurthle Cell

GO Terms for Thyroid Carcinoma, Hurthle Cell

Sources for Thyroid Carcinoma, Hurthle Cell

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....